A clinical trial of radiosurgery to the celiac plexus to overcome pain
An international study to assess the efficacy of a new technique to reduce pain and improve quality of life amongst pancreatic cancer patients suffering from pain.
Details of the study
Many cancer patients, especially those with pancreatic cancer, suffer from severe lower back / upper abdominal pain.
This pain is often poorly managed with standard treatments; the doses of painkiller required often induce side effects, whereas nerve block procedures (where a needle is deeply inserted into the back) are both invasive and of limited benefit.
This clinical trial investigates a unique novel approach in which high-dose radiation (radiosurgery) is focused on the offending nerve bundle (the celiac plexus) in the posterior abdomen.
Preliminary results from a single institution pilot trial are very promising: pain relief is substantial and side effects minimal. In this multi-center clinical trial, patients will be accrued and receive treatment at several international locations.
This trial aims to bring pain relief to cancer sufferers and improve current acceptable standard of care.
The trial resonates with the Gateway mission of promoting new treatments that directly benefit people living with cancer, enhancing their wellbeing, and consequently decreasing the fear associated with a cancer diagnosis.
Dr Yaacov Lawrence, principal investigator:
Dr Yaacov Lawrence MA MBBS MRCP graduated from Cambridge University and University College Hospital, London. He is board certified in Internal Medicine and Radiation Oncology.
Between 2007-2010 he was a Fellow and subsequently Attending Physician at Thomas Jefferson University, Philadelphia.
In 2009 he was awarded an ASCO Young Investigator Award. Currently Dr Lawrence leads the Gastro-intestinal program within the Department of Radiation Oncology, Sheba Medical Center and heads the Research Division within the department.
He is a Senior Lecturer at Tel Aviv University. He has received funding from the Israel Cancer Association, the Israel Science Foundation, Israel Cancer Research Fund, NATO, European Union FP7 program, NATO, the Rosetree’s foundation, Pharmaceutical companies, and Gateway for Cancer Research.